Endocrine Peptide Test Market Share, Trends And Growth By 2034


Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics

How Has the Endocrine Peptide Test Market Evolved in Terms of Size and Value From 2025 to 2029?
The endocrine peptide test market size has grown strongly in recent years. It will grow from $9.11 billion in 2024 to $9.95 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increasing government spending, rising prevalence of diabetes, decreasing level of immunity in people across the world, high risk of contracting any chronic diseases, and rising government initiatives.

The endocrine peptide test market size is expected to see strong growth in the next few years. It will grow to " $13.9 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing demand for endocrine peptide test, growth in research and development activities, rise in number of lifestyle diseases, increasing geriatric population, and rising prevalence of diabetes amongst the masses. Major trends in the forecast period include advancement in the endocrine testing method, advancements in product technologies, increasing research and development activities to develop novel testing solutions, growing number of product approval, and shift towards preventive healthcare.

Get your free report sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16675&type=smp

What Are the Dominant Growth Drivers Impacting the Endocrine Peptide Test Market Outlook?
The rising prevalence of diabetes is expected to propel the growth of the endocrine peptide test market going forward. Diabetes refers to a group of diseases that result in high blood sugar (glucose) levels. The prevalence of diabetes is increasing due to factors such as unhealthy diets, sedentary lifestyles, genetic predisposition, and an aging population. Endocrine peptide test, including hemoglobin A1c, fasting plasma glucose, and C-peptide tests, is used in diabetes to diagnose the condition, monitor glucose levels, and assess insulin production and sensitivity. For instance, in June 2024, according to the National Health Service (NHS), UK-based government department, the number of individuals under 40 diagnosed with diabetes increased significantly, rising from 173,166 in 2022 to 216,440 in 2023. This sharp growth underscores a concerning trend of rising diabetes prevalence in younger populations. Therefore, the rising prevalence of diabetes is driving the endocrine peptide test market.

Which Market Segment Offers the Most Significant Growth Opportunities in the Endocrine Peptide Test Market?
The endocrine peptide testmarket covered in this report is segmented –

1) By Test-Type: Dehydroepiandrosterone Sulphate; Progesterone; Luteinizing Hormone; Thyroid Prolactin; Oestradiol; Human Chorionic Gonadotropin; Thyroid-Stimulating Hormone; Other Test-Types
2) By Technology: Mass Spectroscopy; Immunoassay; Chromatography; Nucleic Acid Based; Other Technologies
3) By End-User: Clinics; Healthcare Centers; Hospitals; Commercial Laboratories

Subsegments:
1) By Dehydroepiandrosterone Sulphate (DHEA-S): Immunoassay Tests; Enzyme-Linked Immunosorbent Assay (ELISA); Radioimmunoassay (RIA)
2) By Progesterone: Immunoassay Tests; Chemiluminescence Assays; ELISA Tests
3) By Luteinizing Hormone (LH): Immunoassay Tests; Enzyme Immunoassay (EIA); Radioimmunoassay (RIA)
4) By Thyroid Prolactin: Immunoassay Tests; Chemiluminescence Assays; Radioimmunoassay (RIA)
5) By Oestradiol: Immunoassay Tests; Enzyme-Linked Immunosorbent Assay (ELISA); Radioimmunoassay (RIA)
6) By Human Chorionic Gonadotropin (hCG): Immunoassay Tests; Chemiluminescence Assays; Enzyme Immunoassay (EIA)
7) By Thyroid-Stimulating Hormone (TSH): Immunoassay Tests; Radioimmunoassay (RIA); Enzyme-Linked Immunosorbent Assay (ELISA)
8) Other Test-Types: Cortisol; Insulin; Growth Hormone (GH); Parathyroid Hormone (PTH)

Which Future-Ready Trends Are Expected to Influence the Endocrine Peptide Test Market?
Major companies operating in the endocrine peptide test market are developing immunoassay testing systems to improve endocrine peptide testing accuracy, sensitivity, and speed. These testing systems use antibodies to detect and measure specific peptides in blood or urine samples, providing healthcare professionals with valuable information about hormone levels and endocrine function. For instance, in July 2023, Siemens Healthineers, a German-based healthcare services company, launched Atellica CI Analyzer, a compact system for immunoassay and clinical chemistry testing, including endocrine peptide assays. The analyzer also features a reproductive endocrinology menu that includes anti-Mullerian hormone (AMH) to determine ovarian reserve and sFlt-1 and PlGF (placental growth factor) to aid in the prognosis of preeclampsia. The Atellica CI Analyzer is designed to deliver quality results quickly and consistently, with up to 1000 tests per hour capacity. It provides workflow efficiency and flexibility to help labs meet evolving testing needs.

Who Are the Dominant Players Contributing Significantly to the Endocrine Peptide Test Market Revenue?
Major companies operating in the endocrine peptide test market are Siemens AG, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson and Company, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Sciex, Bio-Techne Corporation, Invitae Corporation, ARUP Laboratories, Genova Diagnostics, Boston Heart Diagnostics Corporation, Immunodiagnostic Systems Ltd., Mayo Clinic Laboratories

Get the detailed endocrine peptide test market report today
https://www.thebusinessresearchcompany.com/report/endocrine-peptide-test-global-market-report

Which Regions Are Expected to Record the Strongest CAGR in the Endocrine Peptide Test Market?
North America was the largest region in the endocrine peptide test market in 2024. The regions covered in the endocrine peptide test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Comments

Popular posts from this blog

Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Scope, Share Analysis And Growth 2025

Glycomics or Glycobiology Market Scope, Share Analysis And Growth 2025

Smart Crop Monitoring Market Overview, Analysis And Demand By 2034